Valuation: Novavax, Inc.

Market Cap 1.6B 1.4B 1.29B 1.2B 2.27B 152B 2.31B 15.45B 6.01B 74.96B 6.01B 5.88B 258B P/E 2026 *
-20.6x
P/E 2027 * -38.3x
Enterprise Value 1.82B 1.59B 1.46B 1.36B 2.59B 173B 2.63B 17.56B 6.83B 85.21B 6.83B 6.69B 294B EV / Sales 2026 *
4.44x
EV / Sales 2027 * 7.37x
Free-Float
93.03%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 23/01/2023
Director of Finance/CFO 60 16/08/2021
Chief Tech/Sci/R&D Officer - 01/01/2022
Director TitleAgeSince
Director/Board Member 73 06/08/2010
Director/Board Member 66 01/11/2018
Director/Board Member 60 16/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
-12.33%+1,148.37% - - 1.6B
+1.72%+8.15%+4.59%+10.45% 49.92B
+0.92%+3.93%+399.71%+604.02% 40.23B
+1.89%+8.32%+26.06%-6.27% 34.55B
+2.38%+6.35%+21.25%+55.45% 33.09B
+3.96%+10.67%+8.30%+37.95% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+135.37% 15.92B
+0.78%+2.55%+15.99%+23.75% 13.86B
+3.30%+0.76%+90.23%+93.88% 13.52B
Average +0.83%+5.82%+79.95%+119.33% 27.3B
Weighted average by Cap. +2.10%+6.53%+90.78%+136.64%

Financials

2026 *2027 *
Net sales 410M 358M 329M 307M 582M 39.04B 591M 3.95B 1.54B 19.19B 1.54B 1.51B 66.12B 258M 226M 208M 194M 367M 24.61B 373M 2.49B 969M 12.1B 970M 949M 41.69B
Net income -79.31M -69.33M -63.71M -59.39M -113M -7.55B -114M -765M -297M -3.71B -298M -291M -12.79B -43.22M -37.78M -34.72M -32.37M -61.39M -4.12B -62.32M -417M -162M -2.02B -162M -159M -6.97B
Net Debt 219M 191M 176M 164M 311M 20.85B 316M 2.11B 821M 10.25B 822M 804M 35.32B 303M 265M 244M 227M 431M 28.87B 437M 2.92B 1.14B 14.19B 1.14B 1.11B 48.9B
Logo Novavax, Inc.
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-